LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

18.27 0.38

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.9

Max

18.64

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -10M
Darbuotojai	31
EBITDA	131K -10M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+74.15% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	869M 1.4B
Ankstesnė atidarymo kaina	17.89
Ankstesnė uždarymo kaina	18.27

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-27 23:53; UTC

Karštos akcijos

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

2026-02-27 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

2026-02-27 17:55; UTC

Karštos akcijos

Toronto Stocks Decline, But Remain On Track for Weekly Gains

2026-02-27 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

2026-02-27 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

2026-02-27 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-02-27 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-27 21:30; UTC

Uždarbis

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

2026-02-27 21:30; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

2026-02-27 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

2026-02-27 21:17; UTC

Uždarbis

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

2026-02-27 21:10; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

2026-02-27 21:09; UTC

Įsigijimai, susijungimai, perėmimai

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

2026-02-27 21:00; UTC

Uždarbis

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

2026-02-27 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

2026-02-27 20:24; UTC

Rinkos pokalbiai

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

2026-02-27 20:23; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

2026-02-27 20:12; UTC

Rinkos pokalbiai

Nike Seen With Further Challenges in China -- Market Talk

2026-02-27 19:44; UTC

Rinkos pokalbiai

Gold Caps Historic Month -- Market Talk

2026-02-27 19:39; UTC

Uždarbis

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

2026-02-27 19:38; UTC

Uždarbis

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

2026-02-27 18:53; UTC

Įsigijimai, susijungimai, perėmimai

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

2026-02-27 18:45; UTC

Uždarbis

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

2026-02-27 18:45; UTC

Rinkos pokalbiai

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

2026-02-27 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-27 17:07; UTC

Uždarbis

Pemex Cuts 4Q Loss As Operating Results Improve

2026-02-27 17:00; UTC

Rinkos pokalbiai

Corn Rides Oil Momentum Higher -- Market Talk

2026-02-27 16:31; UTC

Rinkos pokalbiai

Canadian Economy Shows Resilience -- Market Talk

2026-02-27 16:17; UTC

Rinkos pokalbiai

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

2026-02-27 15:49; UTC

Uždarbis

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

74.15% į viršų

12 mėnesių prognozė

Vidutinis 31.8 USD 74.15%

Aukščiausias 42 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.